MapLight Therapeutics (MPLT) Cash & Equivalents (2024 - 2025)
MapLight Therapeutics recorded quarterly Cash & Equivalents of $46.7 million in Q4 2025, down 27.15% quarter-over-quarter from $64.1 million in Q3 2025, and up 22.16% year-over-year from $38.3 million in Q4 2024.
MapLight Therapeutics' Cash & Equivalents history runs 2 years deep, the most recent figure standing at $46.7 million for Q4 2025.
- In Q4 2025, Cash & Equivalents rose 22.16% year-over-year to $46.7 million; the TTM figure through Dec 2025 stood at $46.7 million (up 22.16% YoY), while the FY2025 annual figure was $46.7 million, up 22.16% from the prior year.
- Cash & Equivalents came in at $46.7 million for Q4 2025 at MapLight Therapeutics, down from $64.1 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $64.1 million in Q3 2025 to a low of $38.3 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.71 Bn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | 46.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46.73 Mn |
| Sep 30, 2025 | 64.15 Mn |
| Dec 31, 2024 | 38.25 Mn |